We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.01B
AUM Growth
+$262M
Cap. Flow
-$162M
Cap. Flow %
-2.7%
Top 10 Hldgs %
51.52%
Holding
592
New
224
Increased
125
Reduced
42
Closed
159

Top Buys

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$107M
2
GILD icon
Gilead Sciences
GILD
+$99.5M
3
CVS icon
CVS Health
CVS
+$61M
4
BAX icon
Baxter International
BAX
+$57.9M
5
CGEM icon
Cullinan Oncology
CGEM
+$45.6M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$136M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$80.7M
3
SWTX
SpringWorks Therapeutics
SWTX
+$63.2M
4
OSCR icon
Oscar Health
OSCR
+$44.4M
5
VKTX icon
Viking Therapeutics
VKTX
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 83.29%
2 Industrials 0.69%
3 Technology 0.57%
4 Financials 0.44%
5 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
51
Foghorn Therapeutics
FHTX
$305M
$14.5M 0.24%
+2,518,500
New +$15M
CGON icon
52
CG Oncology
CGON
$6.34B
$13.7M 0.23%
433,540
+386,000
+812% +$13.4M
VTYX
53
DELISTED
Ventyx Biosciences
VTYX
$13.5M 0.22%
5,829,570
+2,287,570
+65% +$9.5M
TNGX icon
54
Tango Therapeutics
TNGX
$4.65B
$13.2M 0.22%
1,540,000
– –
APGE icon
55
Apogee Therapeutics
APGE
$10.1B
$12.9M 0.22%
329,000
– –
AUTL
56
Autolus Therapeutics
AUTL
$383M
$12.7M 0.21%
3,639,000
– –
ACCD
57
DELISTED
Accolade Inc
ACCD
$12.4M 0.21%
3,475,000
+1,092,898
+46% +$8.28M
FATE icon
58
Fate Therapeutics
FATE
$324M
$11.7M 0.19%
3,555,871
+1,365,463
+62% +$5.98M
TXG icon
59
10x Genomics
TXG
$5.55B
$11.6M 0.19%
+597,000
New +$15.6M
ITOS
60
DELISTED
iTeos Therapeutics
ITOS
$10.7M 0.18%
723,000
– –
SLDB icon
61
Solid Biosciences
SLDB
$858M
$9.89M 0.16%
1,743,398
-517,000
-23% -$4.63M
EYPT icon
62
EyePoint Inc
EYPT
$1.12B
$7.64M 0.13%
877,790
+298,196
+51% +$4.17M
ALEC icon
63
Alector
ALEC
$167M
$5.21M 0.09%
1,148,326
+75,481
+7% +$388K
PRME icon
64
Prime Medicine
PRME
$565M
$4.61M 0.08%
896,960
+11,646
+1% +$70.6K
PHR icon
65
Phreesia
PHR
$662M
$4.08M 0.07%
+192,347
New +$4.17M
CALC icon
66
CalciMedica
CALC
$11.6M
$3.96M 0.07%
1,000,000
– –
GUTS icon
67
Fractyl Health
GUTS
$129M
$3.56M 0.06%
834,254
– –
CABA icon
68
Cabaletta Bio
CABA
$461M
$3.47M 0.06%
464,252
-794,398
-63% -$9.74M
ANNX icon
69
Annexon
ANNX
$950M
$2.86M 0.05%
583,913
– –
JBIO
70
Jade Biosciences
JBIO
$1.27B
$2.34M 0.04%
+40,332
New +$26.7M
KWR icon
71
Quaker Houghton
KWR
$2.62B
$2.21M 0.04%
+13,015
New +$2.4M
DRI icon
72
Darden Restaurants
DRI
$22.7B
$2.17M 0.04%
14,344
+8,009
+126% +$1.22M
JBL icon
73
Jabil
JBL
$31.5B
$2.14M 0.04%
+19,662
New +$2.38M
PHGE icon
74
BiomX
PHGE
$2.16M
$2.05M 0.03%
32,158
– –
LOW icon
75
Lowe's Companies
LOW
$117B
$1.79M 0.03%
+8,113
New +$1.85M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2024 Portfolio in Review

As of Q2 2024, Deerfield Management held 592 positions worth $6.01B, up 4.6% from $5.75B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q2 2024 filing shows 224 new, 125 increased, 42 reduced and 159 closed positions. Its largest new stake was Waystar Holding Corp: 4,952,004 shares worth $106M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q2 2024 buy was Waystar Holding Corp: 4,952,004 shares worth $106M.
  • Deerfield Management added most to Baxter International in Q2 2024, an estimated $57.9M increase.
  • Deerfield Management's biggest Q2 2024 reduction was Oscar Health, cutting an estimated $44.4M.
  • Deerfield Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $136M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.01B portfolio in Q2 2024.
  • Deerfield Management opened 224 new positions and closed 159 in Q2 2024.
  • Deerfield Management's portfolio value rose 4.6% quarter-over-quarter to $6.01B.

Based on Deerfield Management's 13F filing for Q2 2024, filed 14 Aug 2024.